In This Article:
In the last week, the United Kingdom market has stayed flat, but over the past 12 months, it has risen by 7.1%, with earnings expected to grow by 14% per annum in the coming years. In this promising environment, identifying high growth tech stocks that align with these positive trends can be crucial for investors looking to capitalize on future opportunities.
Top 10 High Growth Tech Companies In The United Kingdom
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
STV Group | 13.15% | 46.78% | ★★★★★☆ |
Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
YouGov | 14.29% | 29.79% | ★★★★★☆ |
Facilities by ADF | 52.00% | 144.70% | ★★★★★☆ |
Redcentric | 4.89% | 63.79% | ★★★★★☆ |
Windar Photonics | 63.60% | 126.92% | ★★★★★☆ |
IQGeo Group | 11.49% | 63.61% | ★★★★★☆ |
Beeks Financial Cloud Group | 24.63% | 57.95% | ★★★★★☆ |
Oxford Biomedica | 20.98% | 106.13% | ★★★★★☆ |
Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Click here to see the full list of 48 stocks from our UK High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Nexxen International
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nexxen International Ltd. offers an end-to-end software platform for advertisers to connect with publishers in Israel and has a market cap of £410.40 million.
Operations: Nexxen International Ltd. generates revenue primarily through its marketing services, amounting to $339.02 million. The company provides a comprehensive software platform that facilitates connections between advertisers and publishers in Israel.
Nexxen International is distinguishing itself in the UK's tech landscape, notably through strategic partnerships and robust R&D investment. Recently, Nexxen has enhanced its market position by partnering with The Trade Desk and Vevo, leveraging its unique automatic content recognition (ACR) data to offer advanced advertising solutions across multiple platforms. This move not only broadens their service offerings but also aligns with current trends towards more targeted and efficient advertising technologies. Financially, Nexxen is on a positive trajectory with a significant turnaround in net income from a loss of $5.61 million to a profit of $2.92 million in Q2 2024 alone, reflecting an impressive recovery. Moreover, the company's commitment to innovation is evident from its R&D spending which remains integral to its strategy for sustaining long-term growth amidst competitive markets. The company's recent share buyback program further underscores their confidence in their financial health and future prospects; repurchasing shares worth $3.7 million signals a strong balance sheet and shareholder value focus. With projected revenue growth at 8.8% per year—outpacing the UK market average—and earnings expected to surge by 71.9% annually, Nexxen appears well-positioned for continued expansion within the high-tech sector of the UK economy.
-
Delve into the full analysis health report here for a deeper understanding of Nexxen International.
-
Explore historical data to track Nexxen International's performance over time in our Past section.
Oxford Biomedica
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oxford Biomedica plc is a contract development and manufacturing organization dedicated to delivering therapies globally, with a market cap of £397.14 million.
Operations: Oxford Biomedica plc operates as a contract development and manufacturing organization, specializing in the production of advanced therapies. The company focuses on delivering innovative treatments to patients around the world.
Oxford Biomedica is navigating through a transformative phase, marked by a robust pipeline and strategic executive enhancements. With recent revenue figures reaching £50.81 million, up from £43.06 million last year, the company is on an upward trajectory despite current unprofitability. The appointment of Lucinda Crabtree as CFO introduces fresh financial acumen, potentially steering the firm towards its forecasted annual profit growth of 106.1%. Moreover, Oxford Biomedica's commitment to R&D is evident in its strategy to ramp up innovation within biotechnology—a sector where it anticipates revenue growth at 21% annually over the next three years, significantly outpacing the UK market average of 3.8%.
-
Click to explore a detailed breakdown of our findings in Oxford Biomedica's health report.
-
Understand Oxford Biomedica's track record by examining our Past report.
Sage Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: The Sage Group plc, along with its subsidiaries, offers technology solutions and services for small and medium businesses across the United States, the United Kingdom, France, and internationally, with a market cap of £10.23 billion.
Operations: Sage Group generates revenue primarily from Europe (£595 million), North America (£1.01 billion), and the United Kingdom & Ireland (£488 million). The company focuses on providing technology solutions and services to small and medium businesses internationally.
Sage Group, a stalwart in the software sector, is setting a robust pace with its strategic focus on enhancing Sage Business Cloud. In its recent quarterly update, revenue surged by 9% to £585 million, underpinned by consistent growth across its cloud offerings. This performance is part of a broader trend where the company's total revenue for nine months climbed to £1.737 billion from £1.589 billion year-on-year. Notably, Sage has integrated VoPay's payment technology into its platform, significantly streamlining payroll processes for SMBs—a move that not only addresses efficiency but also positions it advantageously as businesses increasingly pivot towards comprehensive, automated financial solutions. Moreover, this integration aligns with industry shifts towards embedded financial services, enhancing user experience and operational reliability in Sage’s offerings.
-
Click here to discover the nuances of Sage Group with our detailed analytical health report.
-
Evaluate Sage Group's historical performance by accessing our past performance report.
Seize The Opportunity
-
Delve into our full catalog of 48 UK High Growth Tech and AI Stocks here.
-
Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
-
Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Seeking Other Investments?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
-
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:NEXN LSE:OXB and LSE:SGE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]